found that the IFN-γ/JAK/STAT/TET2 signaling pathway is involved in influencing tumor immunity, and that stimulating TET2 activity increases the efficacy of anti-PD-L1 drugs in solid tumors (15). Here, TET2 is linked to neoplasm.